Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

On Friday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $932.06 which represents a slight increase of $21.37 or 2.35% from the prior close of $910.69. The stock opened at ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Lilly China Medical Innovation Center and Lilly Gateway Lab will further advance Eli Lilly's 100-year business plan, said ...

The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...